Voxeleron

Executive Summary

Voxeleron provides a cloud-based platform for analyzing and tracking ophthalmic clinical trial data, enabling CROs, reading centers, sponsors, and clinical sites to generate more accurate endpoints and access data quickly from any device. Founded in 2009 and based in Pleasanton, California, the company leverages artificial intelligence and machine learning to streamline the analysis of complex imaging data, reducing variability and accelerating trial timelines. With its software-as-a-service model, Voxeleron addresses a critical bottleneck in ophthalmology trials, where precise endpoint measurement is essential for regulatory success. The company is currently in Phase 2 development, likely conducting validation studies or early commercialization efforts. Voxeleron operates in the competitive landscape of ophthalmic imaging analytics, serving a growing market driven by an aging population and increasing prevalence of retinal diseases. Its differentiation lies in its specialized focus on clinical trial workflows and ability to integrate with existing systems. As the ophthalmic clinical trial market expands, Voxeleron is well-positioned to capture share through its scalable platform. Growth catalysts include securing FDA clearance for its software, forming strategic partnerships with leading CROs, and publishing validation data that demonstrate superior endpoint accuracy. The company’s private status suggests it may seek additional funding to support commercialization and product development.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for AI-Powered Endpoint Analysis Software70% success
• Q4 2026Strategic Partnership with a Top-10 CRO for Exclusive Use in Retinal Trials50% success
• Q1 2027Publication of Validation Study Demonstrating Superior Inter-Reader Agreement80% success